Targeting Glutamine Metabolism in Prostate Cancer.

Male Humans Glutamine / metabolism Prostatic Neoplasms / drug therapy Signal Transduction Homeostasis Oxidation-Reduction Tumor Microenvironment
MYC PTEN androgen receptor castrate-resistance glutaminase glutamine mTOR prostate cancer

Journal

Frontiers in bioscience (Elite edition)
ISSN: 1945-0508
Titre abrégé: Front Biosci (Elite Ed)
Pays: Singapore
ID NLM: 101485240

Informations de publication

Date de publication:
04 01 2023
Historique:
received: 17 03 2022
revised: 25 06 2022
accepted: 05 07 2022
entrez: 23 3 2023
pubmed: 24 3 2023
medline: 28 3 2023
Statut: ppublish

Résumé

Glutamine is a conditionally essential amino acid important for cancer cell proliferation through intermediary metabolism leading to

Identifiants

DOI: 10.31083/j.fbe1501002 PMID: 36959101
pubmed: 36959101
pii: S1945-0494(22)00083-2
doi: 10.31083/j.fbe1501002
doi:

Substances chimiques

Glutamine 0RH81L854J

Types de publication

Journal Article Review Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2

Informations de copyright

© 2023 The Author(s). Published by IMR Press.

Déclaration de conflit d'intérêts

Neil Bhowmick: Leadership – Kairos Pharma Lmt., Armida Labs, Inc. Consulting: TRACON Pharma., Cellgene, Xencor. Research funding: Xencor. Edwin Posadas: Consulting or Advisory Role – CytoLumina, Genentech/Roche, Janssen Oncology, Janssen Oncology, Novartis; Speakers’ Bureau – Bayer; Research Funding – Pfizer; Patents, Royalties, Other Intellectual Property – Patent on NanoVelcro Assay for CTCs in prostate cancer; Travel, Accommodations, Expenses – TRACON Pharma. Stephen Freedland: Consulting or Advisory Role – Merck, Astellas, AstraZeneca, Pfizer, Janssen, Bayer, Clovis, Sanofi, Myovant, and Exact Sciences. Robert Figlin: Leadership – 4Dx, Apollomics; Consulting or Advisory Role – Bristol-Myers Squibb, CBT Pharmaceuticals, Johnson & Johnson; Research Funding – Bristol-Myers Squibb (Inst), Calithera Biosciences (Inst), Exelixis (Inst), Merck (Inst), Peloton Therapeutics (Inst). Jun Gong: Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas and Amgen. All other authors report no other conflicts of interest in this work.

Auteurs

Neil Bhowmick (N)

Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Edwin Posadas (E)

Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Leigh Ellis (L)

Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Stephen J Freedland (SJ)

Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Dolores Di Vizio (DD)

Department of Surgery, Division of Cancer Biology and Therapeutics, Biomedical Sciences, and Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Michael R Freeman (MR)

Department of Surgery, Division of Cancer Biology and Therapeutics, Biomedical Sciences, and Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Dan Theodorescu (D)

Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Department of Surgery, Division of Cancer Biology and Therapeutics, Biomedical Sciences, and Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Robert Figlin (R)

Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Jun Gong (J)

Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting Glutamine Metabolism in Prostate Cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés neutres › Glutamine › Targeting Glutamine Metabolism in Prostate Cancer.
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Targeting Glutamine Metabolism in Prostate Cancer.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Targeting Glutamine Metabolism in Prostate Cancer.
questionsmedicales.fr › Phénomènes physiologiques › Homéostasie › Targeting Glutamine Metabolism in Prostate Cancer.
questionsmedicales.fr › Métabolisme › Métabolisme énergétique › Oxydoréduction › Targeting Glutamine Metabolism in Prostate Cancer.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Targeting Glutamine Metabolism in Prostate Cancer.